Skip to content

Study · Non-randomized trial · n = 6 · 1993

7 results

Growth hormone (GH) profiles in response to continuous subcutaneous infusion of GH-releasing hormone(1-29)-NH2 in children with GH deficiency.

Tauber MT, Pienkowski C, Pigeon P, Cataldi M, Rochiccioli P

Acta paediatrica (Oslo, Norway : 1992). Supplement1 Mar 1993

PMID8329829 (opens in a new tab)DOI10.1111/j.1651-2227.1993.tb12832.x (opens in a new tab)PepBankPUB-08329829
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In six children with partial growth hormone deficiency, continuous subcutaneous GHRH(1-29)-NH2 first increased the 24-hour integrated GH concentration from 1.6 to 3.5 micrograms/l/minute.

    In plain wordsIn children with partly low growth hormone, GHRH infusion first raised 24-hour growth hormone levels.

    Peptide
    Sermorelin
    Outcome
    Increase24-hour integrated GH concentration, early phase
    Study

    n = 6

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · continuous subcutaneous infusion · 6 monthsAs given in this study (human).

    Measurements

    24-hour integrated GH
    1.6 micrograms/l/minute
    baseline
    24-hour integrated GH
    3.5 micrograms/l/minute
    early phase

    Source sentences

    Summary
    After an early substantial increase in the 24-hour integrated concentration of GH, from 1.6 +/- 0.1 to 3.5 +/- 0.7 micrograms/l/minute
    1 context sentence
    Summary · context
    Six children presenting with partial growth hormone (GH) deficiency (mean GH peak in two different tests, 8.0 +/- 1.3 micrograms/l) aged 8-10.3 years (mean, 2.7 +/- 0.9 years) were treated for 6 months by continuous subcutaneous infusion of GH-releasing hormone(1-29)-NH2 (GHRH(1-29)-NH2); 24-hour GH…
  2. 02HumanNon-randomized trialEfficacy outcome

    In six children with partial growth hormone deficiency, the 24-hour integrated GH concentration then decreased by 3 months and was lower still after 6 months of GHRH(1-29)-NH2 infusion (1.9 micrograms/l/minute).

    In plain wordsIn children with partly low growth hormone, 24-hour growth hormone levels later fell again during continued GHRH infusion.

    Peptide
    Sermorelin
    Outcome
    Decrease24-hour integrated GH concentration, later decrease
    Study

    n = 6

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · continuous subcutaneous infusion · 6 monthsAs given in this study (human).

    Measurements

    24-hour integrated GH
    1.9 micrograms/l/minute
    6 months

    Source sentences

    Summary
    a subsequent consistent decrease occurred by 3 months, which was more pronounced after 6 months (mean 24-hour integrated concentration of GH, 1.9 +/- 0.9 micrograms/l/minute).
    1 context sentence
    Summary · context
    Six children presenting with partial growth hormone (GH) deficiency (mean GH peak in two different tests, 8.0 +/- 1.3 micrograms/l) aged 8-10.3 years (mean, 2.7 +/- 0.9 years) were treated for 6 months by continuous subcutaneous infusion of GH-releasing hormone(1-29)-NH2 (GHRH(1-29)-NH2); 24-hour GH…
  3. 03HumanNon-randomized trialMechanism

    In children with partial growth hormone deficiency, the biphasic GH effect of GHRH(1-29)-NH2 infusion reflected modification of both pulse amplitude and frequency of GH secretion.

    In plain wordsIn children with partly low growth hormone, GHRH infusion changed both the size and the number of growth hormone pulses.

    Peptide
    Sermorelin
    Outcome
    Not applicablePulse amplitude and frequency of GH secretion
    Study

    n = 6

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · continuous subcutaneous infusion · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    This effect reflects modification of both pulse amplitude and frequency of GH secretion.
    1 context sentence
    Summary · context
    Six children presenting with partial growth hormone (GH) deficiency (mean GH peak in two different tests, 8.0 +/- 1.3 micrograms/l) aged 8-10.3 years (mean, 2.7 +/- 0.9 years) were treated for 6 months by continuous subcutaneous infusion of GH-releasing hormone(1-29)-NH2 (GHRH(1-29)-NH2); 24-hour GH…
  4. 04HumanNon-randomized trialEfficacy outcome

    In six children with partial growth hormone deficiency, at the end of GHRH(1-29)-NH2 infusion one child had complete suppression of GH secretion and two others showed only one peak above 5 micrograms/l in 24 hours.

    In plain wordsIn children with partly low growth hormone, by the end of GHRH infusion one child made no growth hormone and two made very little.

    Peptide
    Sermorelin
    Outcome
    DecreaseGH secretion suppression at end of study
    Study

    n = 6

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · continuous subcutaneous infusion · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    At the end of the study, one child had complete suppression of GH secretion and two others showed only one peak above 5 micrograms/l during a 24-hour period.
    1 context sentence
    Summary · context
    Six children presenting with partial growth hormone (GH) deficiency (mean GH peak in two different tests, 8.0 +/- 1.3 micrograms/l) aged 8-10.3 years (mean, 2.7 +/- 0.9 years) were treated for 6 months by continuous subcutaneous infusion of GH-releasing hormone(1-29)-NH2 (GHRH(1-29)-NH2); 24-hour GH…
  5. 05HumanNon-randomized trialEfficacy outcome

    In children with partial growth hormone deficiency treated with GHRH(1-29)-NH2 infusion, no correlation was found between the GH changes and height velocity.

    In plain wordsIn children with partly low growth hormone, the growth hormone changes during GHRH infusion were not linked to height growth rate.

    Peptide
    Sermorelin
    Outcome
    No significant changeCorrelation of GH changes with height velocity
    Study

    n = 6

    Outcome group
    Linear growth · Endocrine and hormones
    Studied dose
    Dose not stated · continuous subcutaneous infusion · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    No correlation was found between these changes and height velocity.
    1 context sentence
    Summary · context
    Six children presenting with partial growth hormone (GH) deficiency (mean GH peak in two different tests, 8.0 +/- 1.3 micrograms/l) aged 8-10.3 years (mean, 2.7 +/- 0.9 years) were treated for 6 months by continuous subcutaneous infusion of GH-releasing hormone(1-29)-NH2 (GHRH(1-29)-NH2); 24-hour GH…
  6. 06HumanNon-randomized trialEfficacy outcome

    In six children with partial growth hormone deficiency, three children did not grow significantly and three had a growth response to GHRH(1-29)-NH2 infusion.

    In plain wordsIn children with partly low growth hormone, only three of six grew faster with GHRH infusion.

    Peptide
    Sermorelin
    Outcome
    MixedGrowth response (height velocity)
    Study

    n = 6

    Outcome group
    Linear growth · Endocrine and hormones
    Studied dose
    Dose not stated · continuous subcutaneous infusion · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Three children did not grow significantly; the other three children who had a growth response to GHRH(1-29)-NH2
    1 context sentence
    Summary · context
    Six children presenting with partial growth hormone (GH) deficiency (mean GH peak in two different tests, 8.0 +/- 1.3 micrograms/l) aged 8-10.3 years (mean, 2.7 +/- 0.9 years) were treated for 6 months by continuous subcutaneous infusion of GH-releasing hormone(1-29)-NH2 (GHRH(1-29)-NH2); 24-hour GH…
  7. 07HumanNon-randomized trialOther

    In six children with partial growth hormone deficiency, the three children with a growth response to GHRH(1-29)-NH2 were those with the lowest 24-hour integrated GH concentration at the end of the study.

    In plain wordsIn children with partly low growth hormone, the three who grew faster had the lowest 24-hour growth hormone levels at the end.

    Peptide
    Sermorelin
    Outcome
    Not applicableEnd-of-study GH level in growth responders
    Study

    n = 6

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · continuous subcutaneous infusion · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    the other three children who had a growth response to GHRH(1-29)-NH2 were those with the lowest 24-hour integrated GH concentration at the end of the study.
    1 context sentence
    Summary · context
    Six children presenting with partial growth hormone (GH) deficiency (mean GH peak in two different tests, 8.0 +/- 1.3 micrograms/l) aged 8-10.3 years (mean, 2.7 +/- 0.9 years) were treated for 6 months by continuous subcutaneous infusion of GH-releasing hormone(1-29)-NH2 (GHRH(1-29)-NH2); 24-hour GH…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.